ZIOPHARM Oncology, Inc. (ZIOP) – Financial and Strategic SWOT Analysis Review

ZIOPHARM Oncology, Inc. (ZIOP) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $300

Buy Now
customer(s) bought this report

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Single User
Site License
Pharmaceuticals and Healthcare
United States


ZIOPHARM Oncology, Inc. (ZIOPHARM Oncology) is a biopharmaceutical company. The company discovers and develops cancer therapies. Its products include palifosfamide, IL-12 DNA program, indibulin and darinaparsin. ZIOPHARM Oncology’s indibulin is a tubulin binding agent in phase II clinical trial in metastatic breast cancer; and darinaparsin is a novel organic arsenic molecule synthesized by conjugating dimethylarsenic to glutathione. Its activity includes disruption of mitochondrial function, inhibition of angiogenesis and modified signal transduction, leading to cell cycle arrest and apoptosis. Darinaparsin is active against hematological and solid cancers both in vitro and in vivo. The company partners with Intrexon Corporation. The company was formerly known as EasyWeb, Inc. ZIOPHARM Oncology is headquartered in Boston, Massachusetts, the US.

ZIOPHARM Oncology, Inc. Key Recent Developments

Nov 27, 2013: ZIOPHARM Oncology to Present at the 25th Annual Piper Jaffray Healthcare Conference
Oct 22, 2013: ZIOPHARM and Intrexon Announce Presentation of Data Highlighting Regulated Gene Expression System in Tumor-Homing Mesenchymal Stem Cells
Oct 22, 2013: ZIOPHARM Announces Third Quarter Financial Results and Updates Key Development Activities
Oct 21, 2013: ZIOPHARM and Intrexon Announce Presentation of Data Highlighting Versatility of Novel Gene Expression and Control Technology

This comprehensive SWOT profile of ZIOPHARM Oncology, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of ZIOPHARM Oncology, Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Table of Contents

Section 1 – About the Company

ZIOPHARM Oncology, Inc. – Key Information
ZIOPHARM Oncology, Inc. – Overview
ZIOPHARM Oncology, Inc. – Key Employees
ZIOPHARM Oncology, Inc. – Key Employee Biographies
ZIOPHARM Oncology, Inc. – Key Operational Heads
ZIOPHARM Oncology, Inc. – Major Products and Services
ZIOPHARM Oncology, Inc. – History
ZIOPHARM Oncology, Inc. – Company Statement
ZIOPHARM Oncology, Inc. – Locations And Subsidiaries
ZIOPHARM Oncology, Inc. – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

ZIOPHARM Oncology, Inc. – Business Description
ZIOPHARM Oncology, Inc. – Corporate Strategy
ZIOPHARM Oncology, Inc. – SWOT Analysis
SWOT Analysis – Overview
ZIOPHARM Oncology, Inc. – Strengths
ZIOPHARM Oncology, Inc. – Weaknesses
ZIOPHARM Oncology, Inc. – Opportunities
ZIOPHARM Oncology, Inc. – Threats
ZIOPHARM Oncology, Inc. – Key Competitors

Section 3 – Company Financial Performance Charts

ZIOPHARM Oncology, Inc. – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Ratio Definitions
About GlobalData
Contact Us

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

ZIOPHARM Oncology, Inc., Key Information
ZIOPHARM Oncology, Inc., Key Ratios
ZIOPHARM Oncology, Inc., Share Data
ZIOPHARM Oncology, Inc., Major Products and Services
ZIOPHARM Oncology, Inc., History
ZIOPHARM Oncology, Inc., Key Employees
ZIOPHARM Oncology, Inc., Key Employee Biographies
ZIOPHARM Oncology, Inc., Key Operational Heads
ZIOPHARM Oncology, Inc., Other Locations
ZIOPHARM Oncology, Inc., Subsidiaries
ZIOPHARM Oncology, Inc., Key Manufacturing facilities
ZIOPHARM Oncology, Inc., Key Competitors
ZIOPHARM Oncology, Inc., SWOT Analysis
ZIOPHARM Oncology, Inc., Ratios based on current share price
ZIOPHARM Oncology, Inc., Annual Ratios
ZIOPHARM Oncology, Inc., Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

ZIOPHARM Oncology, Inc., Performance Chart
ZIOPHARM Oncology, Inc., Ratio Charts

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $300

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.